Amylyx Pharmaceuticals (AMLX) Accumulated Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 6.51% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (down 6.51% YoY), while the FY2025 annual figure was $17.9 million, down 25.22% from the prior year.
• Accumulated Expenses was $11.3 million for Q1 2026 at Amylyx Pharmaceuticals, down from $17.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $67.9 million in Q1 2024 to a low of $6.5 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $31.7 million across 5 years, with a median of $23.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses surged 474.8% in 2023, then sank 82.22% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $38.3 million in 2022, then jumped by 50.67% to $57.7 million in 2023, then tumbled by 58.51% to $23.9 million in 2024, then fell by 25.22% to $17.9 million in 2025, then slumped by 37.01% to $11.3 million in 2026.
• The last three Accumulated Expenses figures came in at $11.3 million (Q1 2026), $17.9 million (Q4 2025), and $19.5 million (Q3 2025), per Business Quant data.